This article discusses the case of Sun Pharmaceuticals Sdn Bhd v Wong Fong Leng [2026] 633. The High Court delivers a landmark ruling on breach of fiduciary duty in Malaysia, awarding over RM70 million in a derivative action under the Companies Act 2016. This case discusses the events based on the published case report. In case of any corrections, please contact us.
Introduction – The Sun Pharma Situation
In November 2018, Dr Lim Boon Ping’s marriage to Wong Fong Leng finally collapsed. At that moment, Sun Pharmaceutical Sdn Bhd — the company he had founded twenty-one years earlier — was enjoying record profits, a loyal workforce, and exclusive distributorships with respected foreign principals. What followed, according to the High Court, was not commercial misfortune but a carefully orchestrated dismantling of a thriving business by the very people entrusted to steward it.
The Story Behind the Suit
In 1997, Dr Lim Boon Ping founded Sun Pharmaceutical Sdn Bhd with a straightforward vision: to bring quality health and nutritional products to Malaysian consumers. By the turn of the millennium, the company had secured distributorships and National Pharmaceutical Regulatory Agency (NPRA) licences for imported pharmaceutical products from respected foreign principals — Pharma Nord ApS and Celeste (S) Pte Ltd. For nearly two decades, the business grew steadily, building relationships, reputations, and revenue. The year 2017 marked a high point: record net profits, a thriving workforce, and a brand that carried genuine weight in the market.
But the foundation was cracking. Wong Fong Leng, Dr Lim’s wife, was not merely a director on paper; she was the controlling mind of the company’s daily operations. When their marriage finally broke down in November 2018, the fracture extended beyond the personal into the corporate. What followed, the Court would later describe, was not the natural decline of an ailing business but a deliberate, methodical transfer of corporate lifeblood to new vessels created in the shadows.
Sino Health Sdn Bhd had been incorporated in September 2018, weeks before the marriage’s public collapse. To the outside world, it may have looked like another entrant in the pharmaceutical distribution space. To those inside Sun Pharma, it was becoming something else entirely: a destination for licences that had taken two decades to secure. Mazuriah binti Abu Darin, who had managed regulatory affairs for Sun Pharma, and Gan Jia Swee, who had overseen its finances, were quietly installed as directors of this new entity. The company’s historical distributorships began migrating — first to Sino Health, then to Pharma Nord Sdn Bhd, a local entity that shared a name with the Danish principal but answered to a different master.
The mechanics were as precise as they were damaging. NPRA licence transfer forms appeared bearing Dr Lim’s signature, enabling Wong Fong Leng to bypass the governance safeguards that his equal shareholding was meant to provide. Dr Lim would later testify, consistently and unshaken under cross-examination, that he had never signed these documents. In the witness box, Wong Fong Leng admitted that she had signed the NPRA transfer forms herself, offering the explanation that this had long been the practice between husband and wife. The Court found that explanation incredible. The signatures were not genuine; the impression of consent was false.
The physical dismantling followed the regulatory. Entire inventories — nutritional supplements, pharmaceutical stocks, the material substance of the business — were transferred to Pharma Nord for RM30,000.00, a sum that bore no relation to their audited book value of over RM9 million. Office equipment, computers, mobile phones, and renovations were bundled into the same transaction. Staff were redirected to new premises. The website that had long served as Sun Pharma’s digital storefront began redirecting visitors to Pharma Nord’s platform. On Instagram, Pharma Nord announced the transition with a casual confidence that belied the devastation: “Your trusted health partner Sun Pharma is now PharmaNord Malaysia… Thank you for your relentless support and confidence in us.”
For Dr Lim, the response was not acceptance but litigation. He fought to restore his 50% shareholding after forged transfers — a battle that ended in a consent judgment in May 2019. He sought access to accounting records, obtained it, and saw that decision upheld by the Court of Appeal. He secured leave to bring this derivative action in October 2020. At every turn, Wong Fong Leng resisted: she sought to stay the derivative proceedings pending divorce, failed; she petitioned to wind up Sun Pharma, failed; and by February 2024, she had been fined RM50,000 for contempt for refusing to comply with an inspection order. The litigation stretched across six related proceedings and multiple appellate stages before the 19-day trial finally commenced, hearing evidence from six witnesses including the foreign principals themselves.
The Legal Battle: Arguments of the Parties
The Plaintiff’s Position
Led by Dhinesh Bhaskaran, Sun Pharma’s case rested on four pillars. First, Wong Fong Leng had breached her statutory fiduciary duties under sections 213 and 218 of the Companies Act 2016 by diverting corporate opportunities, assets, and regulatory licences to Sino Health and Pharma Nord. Second, she had forged documents and misled foreign principals to engineer the termination of Sun Pharma’s distributorships, circumventing Dr Lim’s equal shareholding rights. Third, Mazuriah and Gan Jia Swee, despite their employment status, had breached duties of fidelity and fiduciary obligations by actively assisting in the diversion of assets, licences, and personnel to a competing vehicle. Fourth, the losses were quantifiable, documented in audited accounts, and directly caused by the defendants’ conduct — amounting to a comprehensive claim for historical profits, future profits, lost goodwill, and misappropriated assets.
Wong Fong Leng’s Defence
Robert Lazar, for Wong Fong Leng, mounted a vigorous defence. There was no direct evidence of forgery or dishonest intent, he argued. The foreign principals had acted independently; their decisions to terminate distributorships were commercial, not coerced. She held no shares in Sino Health or Pharma Nord and had received no personal benefit from either entity. The wholesale arrangement that replaced the distributorships was a salvage operation intended to safeguard Sun Pharma’s viability, not sabotage it. Without direct evidence of misappropriation, the Plaintiff had not met its burden of proof.
The Senior Employees’ Defence
Brendan Navin Siva, for Mazuriah and Gan Jia Swee, contended that fiduciary duties were exceptional, not default. Citing Smile Inc Dental Surgeons v Lui Andrew Stewart, he submitted that mere employees acting under the direction of a controlling director could not be saddled with fiduciary liability. Their appointments to Sino Health were at the principals’ request and with Wong Fong Leng’s full knowledge. Their involvement was neither clandestine nor motivated by personal gain. If the Court found any breach, section 581 of the Companies Act 2016 provided a statutory lifeline: they had acted honestly, reasonably, and ought fairly to be excused.
Key Authorities and Laws Considered by the Court
Statutes
- Companies Act 2016, s 213(1): Imposes the fundamental duty on directors to exercise their powers in good faith and in the best interests of the company.
- Companies Act 2016, s 218(1)(b)–(e): Prohibits directors and officers from using company property, information, position, opportunities, or engaging in competing business to gain a benefit for themselves or others without general meeting consent.
- Companies Act 2016, s 351: Empowers the Court to grant injunctions restraining conduct that contravenes the Act and to order performance of statutory obligations.
- Companies Act 2016, s 581: Provides discretionary relief for officers who have acted honestly and reasonably and ought fairly to be excused for negligence, default, breach of duty, or breach of trust.
Case Authorities
- Bristol and West Building Society v Mothew [1998] Ch 1: Defined the fiduciary relationship as one of single-minded loyalty, good faith, and avoidance of conflict. The Court adopted this as the foundational statement of fiduciary principle.
- Soh Chee Gee v Syn Tai Hung Trading Sdn Bhd [2019] 2 MELR 169; [2019] 2 MLRA 661: Clarified that fiduciary status for employees depends on the nature of duties undertaken and the degree of trust and responsibility conferred, not merely on seniority or job title.
- Smile Inc Dental Surgeons v Lui Andrew Stewart [2012] 4 SLR 308: Relied upon by the defendants for the proposition that fiduciary duties arise only in exceptional circumstances of trust and influence. The Court distinguished its application on the facts.
- Ngeow Voon Yean v Sungei Wang Plaza Sdn Bhd / Landmarks Holding Bhd [2006] 1 MELR 105; [2006] 1 MLRA 870: Cited by the defendants in support of the argument that liability should not arise where no personal benefit is obtained.
- Dagang Nexchange Berhad & Ors v Mohd Ismail Khan Wazir Khan [2026] 1 MLRH 123: A recent Malaysian decision recognising that senior employees entrusted with strategic functions may owe fiduciary obligations.
- Karen Yap Chew Ling v Binary Group Services Bhd & Another Appeal [2023] 5 MLRA 587: Adopted by the Court for the principle that full compensation must be awarded and any doubt resolved in favour of the victim of the breach.
- Newacres Sdn Bhd v Sri Alam Sdn Bhd [2000] 1 MLRA 184: Reinforced the restitutionary principle that the plaintiff must be placed in the position it would have occupied but for the breach.
- Rookes v Barnard [1964] AC 1129: The House of Lords authority governing exemplary damages, applied to punish oppressive, arbitrary, or calculated misconduct.
- Bank Bumiputra Malaysia Bhd Kuala Terengganu v Mae Perkayuan Sdn Bhd & Anor [1993] 1 MLRA 198 and Lembaga Kemajuan Tanah Persekutuan (Felda) & Anor v Awang Soh Mamat & Ors [2009] 2 MLRA 1: Malaysian appellate authorities confirming that exemplary damages are appropriate where wrongdoing is intentional, sustained, and motivated by personal benefit.
The Court’s Decision: Plain English Explanation
On 1 December 2025, Yusrin Faidz Yusoff JC delivered a comprehensive judgment allowing Sun Pharma’s claim against all three defendants.
The Director’s Liability
The Court found that Wong Fong Leng, as director and controlling mind, owed the highest duty of loyalty under sections 213 and 218 of the Companies Act 2016. Fiduciary obligations are not limited to prohibiting dishonest gain; they require active protection of company assets, avoidance of conflicts, and refraining from diverting business opportunities to competing vehicles. The documentary record showed that Sun Pharma was financially stable and operationally active when its entire business was divested to newly formed entities staffed by her own management team. The fabrication of Dr Lim’s signature on NPRA transfer forms was a grave act of dishonesty demonstrating a clear intention to deceive and circumvent governance safeguards. The testimony of the foreign principals confirmed that their decisions to transfer distributorships were influenced by her misrepresentations. She could not escape liability by attributing the dismantling of the business to independent commercial decisions when she had deliberately cultivated the circumstances that caused them.
The Senior Employees’ Liability
The Court rejected the argument that Mazuriah and Gan Jia Swee were mere employees beyond the reach of fiduciary law. While not every employee owes fiduciary duties, the law recognises heightened obligations where an employee is entrusted with strategic functions and significant trust. Their transition from Regulatory Affairs Manager and Finance Manager to directors and shareholders of a competing entity carrying Sun Pharma’s business was plainly adverse to their employer’s interests. The defence of “following instructions” failed: a senior officer’s duty of fidelity requires refraining from acts harmful to the employer, even when directed by a superior. Section 581 relief was denied because their involvement was not incidental; they accepted roles in a company actively receiving Sun Pharma’s assets without transparency or shareholder authorisation. The Court could not say they had acted honestly and reasonably.
Causation and Damages
The Court held that the defendants’ conduct directly caused Sun Pharma’s commercial collapse. The losses were not speculative. Using audited accounts and a benchmark of 2016–2017 average profits, the Court awarded compensatory damages comprising: RM33,211,686.00 for loss of profits (2018–2021); RM8,972,884.00 for assets transferred to Pharma Nord; RM28,802,265.00 for loss of future profits (2022–2026); and RM500,000.00 for loss of goodwill. Wong Fong Leng was additionally ordered to pay RM1,900,521.00 for assets she had personally extracted. These compensatory sums were ordered jointly and severally against all three defendants.
Exemplary damages were also awarded to punish the cynical, calculated, and sustained nature of the misconduct: RM1,000,000.00 against Wong Fong Leng, and RM300,000.00 each against Mazuriah and Gan Jia Swee. Interest was awarded at 5% per annum from the date of judgment, and injunctive relief under section 351 of the Companies Act 2016 was granted to restrain all three defendants from participating in the shareholding, management, or operations of Sino Health and Pharma Nord.
Significance and Practical Takeaways
For the Parties
For Dr Lim and Sun Pharma, the judgment represents vindication after years of litigation across multiple forums. The damages award — exceeding RM70 million in aggregate — is designed to restore the company to the position it would have occupied but for the breach. The permanent injunctions prevent the defendants from continuing to benefit from the entities that received the diverted business.
For the Wider Legal and Commercial Community
- Fiduciary duties extend beyond the boardroom. The decision clarifies that employees may owe fiduciary duties depending on the degree of trust reposed and the scope of authority exercised, not merely on job title. Senior officers with access to confidential data, regulatory approvals, and strategic functions should treat this as a live risk.
- Section 581 is a narrow safety valve, not a shield. Subordinate officers cannot assume that “following orders” will guarantee relief. The Court emphasised that section 581 is discretionary and intended only for those who have acted honestly and reasonably. Where directions are manifestly detrimental to the company, blind compliance is no defence.
- Exemplary damages deter corporate abuse. The award of punitive damages signals that Malaysian courts will not hesitate to punish calculated, high-handed misuse of corporate power, particularly where it is designed to strip matrimonial or shareholder value.
- Derivative actions remain a potent remedy. The judgment reinforces the utility of derivative actions under the Companies Act 2016 for shareholders facing oppressive conduct by controlling directors, even where the wrongdoing is concealed behind complex corporate restructuring.
- Governance safeguards matter. The case underscores the importance of robust internal controls, dual-signatory requirements for licence and asset transfers, and clear lines of authority — especially in family-owned businesses where informal practices can mask serious governance failures.
Conclusion
The collapse of Sun Pharma is a cautionary tale about what happens when trust within a company is weaponised rather than honoured. For businesses, the judgment is a reminder that corporate governance is not merely paperwork; it is the architecture that protects a company’s survival. For practitioners, it offers an authoritative roadmap on the scope of fiduciary duties, the liability of senior employees, and the measure of damages in derivative actions. If you are navigating shareholder disputes or concerns about director conduct, early legal advice can mean the difference between preservation and dismantlement.
Important Notice
This article was prepared for educational purposes. If you are facing a similar situation, please consult with a licensed law practitioner before making a final decision. Please do not treat this article as a substitute for competent legal advice rendered by a licensed lawyer. Thank you for reading.